A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)

NCT05104567 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

138

Enrollment

INDUSTRY

Sponsor class

Conditions

Oesophageal Squamous Cell Carcinoma
Gastric Cancer
Hepatocellular Carcinoma
Colorectal Cancer
Oesophageal Adenocarcinoma

Interventions

DRUG: THOR-707
DRUG: Pembrolizumab
DRUG: Cetuximab

Sponsor

Sanofi

Collaborators

[object Object]